Carmoterol

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Carmoterol
Carmoterol.svg
Clinical data
Routes of
administration
Inhalation
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C21H24N2O4
Molar mass 368.43 g·mol−1
3D model (JSmol)

Carmoterol (INN),[1] also known as TA-2005 and CHF-4226, is a non-catechol[2] experimental ultra-long-acting β adrenoreceptor agonist (ultra-LABA)[2][3] that was in clinical trials before 2010 when it has been withdrawn from further development based on evidence that the compound does not possess a competitive profile.[4]

Preliminary studies indicated duration of its effect exceeding 24 hours after inhalation of 3 μg.[2] The pharmacologic profile of this medication included the fact its potency in isolated guinea pig trachea is greater than that of formoterol and salmeterol, it is over 100 times more selective for bronchial muscle than myocardial tissue.[5]

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). WHO Drug Information. 19 (1): 74. 2005. Retrieved 25 March 2016. 
  2. ^ a b c Mario, MD, MPH, Castro; Monica, MD, Kraft (2008). "27. Bronchodilators: Beta2-Agonists and Anticholingercs". Clinical Asthma. 1600 John F. Kennedy Boulevard, Suite 1800, Philadelphia, PA 19103–2899: Mosby / Elsevier Health Sciences. ISBN 978-0-323-04289-5. 
  3. ^ Cazzola, Mario; Calzetta, Luigino; Matera, Maria Gabriella (May 2011). 2-adrenoceptor agonists: current and future direction". British Journal of Pharmacology. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864Freely accessible. PMID 21232045. Retrieved 25 March 2016. 
  4. ^ "Chiesi: Annual Report 2010" (PDF). Chiesi Farmaceutici S.p.A. p. 20. Retrieved 27 March 2016. 
  5. ^ Donohue, MD, James F (2006). "New Options in COPD Therapy". Medscape. Retrieved 27 March 2016.